Abstract
Multicellular layers (MCL) of cancer cells is an in vitro 3-dimensional (3D) model that mimics avascular microregions of human solid tumors and has been shown to be useful in pharmacokinetic–pharmacodynamic studies of anticancer agents. We investigated whether Ki-67, which is widely used as a proliferation marker, can be used to evaluate changes in proliferative fractions following drug exposure in MCL of HT-29 human colorectal cancer cells. Ki-67 expression was monitored and compared between cancer cells cultured as monolayers or MCL. Drug distribution and Ki-67 expression were evaluated within MCL following exposure to doxorubicin and paclitaxel. Ki-67 expression was observed in the nuclei of proliferating cells in monolayers, tumor xenograft, and multicellular spheroids. In MCL, however, Ki-67 expression was detected in the membrane/cytoplasm as well as in the nucleus throughout MCL. Neither the location nor the level of expression changed following drug exposure, whereas drug-induced apoptosis increased. Our data show that membranous/cytoplasmic Ki-67 may not be valid as a marker for the proliferative activity of cells grown as MCL. Studies for non-nuclear localization and its mechanism in 3D in vitro models of other cell lines are warranted.
Similar content being viewed by others
References
Al-Abd, A.M., J.H. Lee, S.Y. Kim, N. Kun, and H.J. Kuh. 2008. Novel application of multicellular layers culture for in situ evaluation of cytotoxicity and penetration of paclitaxel. Cancer Science 99: 423–431.
Campbell-Thompson, M., I.J. Lynch, and B. Bhardwaj. 2001. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Research 61: 632–640.
Clairwood, M., A. LaChance, and M. Murphy. 2011. Cytoplasmic immunoreactivity for Ki67 in an invasive amelanotic melanoma–foe or faux pas? Journal of Cutaneous Pathology 38: 318–319.
Cowan, D.S., K.O. Hicks, and W.R. Wilson. 1996. Multicellular membranes as an in vitro model for extravascular diffusion in tumours. British Journal of Cancer 27: S28–S31.
du Manoir, S., P. Guillaud, E. Camus, D. Seigneurin, and G. Brugal. 1991. Ki-67 labeling in postmitotic cells defines different Ki-67 pathways within the 2c compartment. Cytometry 12: 455–463.
Elliott, N.T., and F. Yuan. 2011. A review of three-dimensional in vitro tissue models for drug discovery and transport studies. Journal of Pharmaceutical Sciences 100: 59–74.
Faratian, D., A. Munro, C. Twelves, and J.M. Bartlett. 2009. Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma. Histopathology 54: 254–257.
Friedrich, J., W. Eder, J. Castaneda, M. Doss, E. Huber, R. Ebner, and L.A. Kunz-Schughart. 2007. A reliable tool to determine cell viability in complex 3-d culture: The acid phosphatase assay. Journal of Biomolecular Screening 12: 925–937.
Gerdes, J., H. Lemke, H. Baisch, H.H. Wacker, U. Schwab, and H. Stein. 1984. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. Journal of Immunology 133: 1710–1715.
Hattori, H. 2002. Sclerosing haemangioma of the lung is positive for MIB-1 in cell membrane and cytoplasmic staining pattern. Histopathology 40: 291–293.
Hirokawa, M., and J.A. Carney. 2000. Cell membrane and cytoplasmic staining for MIB-1 in hyalinizing trabecular adenoma of the thyroid gland. The American Journal of Surgical Pathology 24: 575–578.
Kee, N., S. Sivalingam, R. Boonstra, and J.M. Wojtowicz. 2002. The utility of Ki-67 and BrdU as proliferative markers of adult neurogenesis. Journal of Neuroscience Methods 115: 97–105.
Kyle, A.H., L.A. Huxham, J.H. Baker, H.E. Burston, and A.I. Minchinton. 2003. Tumor distribution of bromodeoxyuridine-labeled cells is strongly dose dependent. Cancer Research 63: 5707–5711.
Kyle, A.H., L.A. Huxham, A.S. Chiam, D.H. Sim, and A.I. Minchinton. 2004. Direct assessment of drug penetration into tissue using a novel application of three-dimensional cell culture. Cancer Research 64: 6304–6309.
Leonardo, E., M. Volante, M. Barbareschi, and A. Cavazza. 2007. Dei Tos, A. P., Bussolati, G., and Papotti, M., Cell membrane reactivity of MIB-1 antibody to Ki67 in human tumors: Fact or artifact? Applied Immunohistochemistry Molecular Morphology 15: 220–223.
MacCallum, D.E., and P.A. Hall. 1999. Biochemical characterization of pKi67 with the identification of a mitotic-specific form associated with hyperphosphorylation and altered DNA binding. Experimental Cell Research 252: 186–198.
Mayot, D., M.C. Béné, C. Perrin, and G.C. Faure. 1993. Restricted expression of Ki-67 in cholesteatoma epithelium. Archives of Otolaryngology: Head and Neck Surgery 119: 656–658.
Minchinton, A.I., and I.F. Tannock. 2006. Drug penetration in solid tumours. Nature Reviews Cancer 6: 583–592.
Ortiz-Rey, J.A., A. Peteiro, and A. Fernández-Costas. 2009. Gómez de María, C., and Antón, I., Cell membrane and cytoplasmic immunoreactivity of MIB-1 in invasive breast carcinoma. Applied Immunohistochemistry Molecular Morphology 17: 563–564.
Padrón, J.M., C.L. van der Wilt, K. Smid, E. Smitskamp-Wilms, H.H. Backus, P.E. Pizao, G. Giaccone, and G.J. Peters. 2000. The multilayered postconfluent cell culture as a model for drug screening. Critical Reviews in Oncology/Hematology 36: 141–157.
Schmidt, M.H., R. Broll, H.P. Bruch, S. Finniss, O. Bögler, and M. Duchrow. 2004. Proliferation marker pKi-67 occurs in different isoforms with various cellular effects. Journal of Cellular Biochemistry 91: 1280–1292.
Scholzen, T., and J. Gerdes. 2000. The Ki-67 protein: From the known and the unknown. Journal of Cellular Physiology 182: 311–322.
Singh, B., R. Li, L. Xu, A. Poluri, S. Patel, A.R. Shaha, D. Pfister, E. Sherman, A. Goberdhan, R.M. Hoffman, and J. Shah. 2002. Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 24: 437–442.
Tashiro, T., M. Hirokawa, H. Harada, S. Yokoyama, and T. Sano. 2002. Cell membrane expression of MIB-1 in salivary gland pleomorphic adenoma. Histopathology 41: 559–561.
Trédan, O., C.M. Galmarini, K. Patel, and I.F. Tannock. 2007. Drug resistance and the solid tumor microenvironment. Journal of the National Cancer Institute 99: 1441–1454.
Urruticoechea, A., I.E. Smith, and M. Dowsett. 2005. Proliferation marker Ki-67 in early breast cancer. Journal of Clinical Oncology 23: 7212–7220.
van Dierendonck, J.H., R. Keijzer, C.J. van de Velde, and C.J. Cornelisse. 1989. Nuclear distribution of the Ki-67 antigen during the cell cycle: Comparison with growth fraction in human breast cancer cells. Cancer Research 49: 2999–3006.
Walker, R.A., and R.S. Camplejohn. 1988. Comparison of monoclonal antibody Ki-67 reactivity with grade and DNA flow cytometry of breast carcinomas. British Journal of Cancer 57: 281–283.
Wong, S.F., Y. da No, Y.Y. Choi, D.S. Kim, B.G. Chung, and S.H. Lee. 2011. Concave microwell based size-controllable hepatosphere as a three-dimensional liver tissue model. Biomaterials 32: 8087–8096.
Xu, H., Y. Yu, D. Marciniak, A.K. Rishi, F.H. Sarkar, O. Kucuk, and A.P. Majumdar. 2005. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. Molecular Cancer Therapeutics 4: 435–442.
Acknowledgments
This work was supported by Mid-career Researcher Program through NRF Grant funded by the MEST (No. 2012R1A2A2A01003361) and the Nano-Biotechnology Project (Regenomics, 2011-0007745) of the Korean Science and Engineering Foundation (KOSEF). Yu-Jin Kim was sponsored by the Ministry of Knowledge Economy (MKE) and Korea Industrial Technology Foundation (KOTEF) through the Human Resource Training Project for Strategic Technology
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, YJ., Lee, SH., Lee, J. et al. Non-nuclear localization of Ki-67 in human colorectal cancer cells grown as multicellular layers. Arch. Pharm. Res. 36, 634–640 (2013). https://doi.org/10.1007/s12272-013-0061-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-013-0061-2